Navigation Links
Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
Date:7/2/2012

SEATTLE, July 2, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors prior to the opening of the market on June 27, 2012, relating to the sale of 3,365,854 shares of its common stock at a price of $10.25 per share for gross proceeds of approximately $34.5 million. The closing included the sale of 439,024 shares of common stock sold pursuant to the overallotment option granted by Omeros to the underwriters, which the underwriters exercised in full. After deducting underwriting discounts and other estimated offering expenses, Omeros will receive net proceeds from the transaction of approximately $32.3 million.

Omeros intends to use the net proceeds of the offering for general corporate purposes, including expenses related to the clinical development of Omeros' two ongoing Phase 3 clinical development programs – OMS302 for use during intraocular lens replacement procedures and OMS103HP for use during arthroscopic partial meniscectomy surgery. The net offering proceeds may also be used to fund research and development in Omeros' preclinical studies and clinical trials, capital expenditures, working capital and to otherwise advance Omeros' product candidates toward commercialization.

Cowen and Company, LLC and Deutsche Bank Securities Inc. acted as the joint book-running managers for the offering, Canaccord Genuity Inc. and Wedbush PacGrow Life Sciences acted as co-managers, and WBB Securities served as a financial advisor to Omeros.

A shelf registration statement (File No. 333-169856) relating to these securities was filed with the Securities and Exchange Commission on October 8, 2010 and declared effective on October 18, 2010. A final prospectus supplement related to the offering was filed with the Securities and Exchange Commission on June 28, 2012. The securities may be offered only by means of a prospectus, including the final prospectus supplement, forming a part of the effective registration statement. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140), or Deutsche Bank Securities Inc., Attn: Prospectus Group, 60 Wall Street, New York, NY 10005-2836 or by telephone at: (800) 503-4611, or by email at: prospectus.CPDG@db.com. An electronic copy of the prospectus supplement and accompanying prospectus relating to the offering is available on the website of the Securities and Exchange Commission at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of Omeros, and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system.

Forward-looking Statements
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding Omeros' expectations regarding the underwritten public offering. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2012. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Prices $30 Million Public Offering of Common Stock
2. Omeros Announces Proposed Public Offering of Common Stock
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
5. Omeros to Present at Deutsche Bank Securities Health Care Conference
6. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
7. MicroVention Announces First Patient Enrollment In Clinical Trial To Compare Coiling Technologies For Treating Brain Aneurysms
8. Omron Healthcare Announces New Pedometers
9. Improved Maintenance and Control of Electronic Health Records. ICAP Patent Brokerage Announces for Auction Patented Techniques for Improved Patient Control and Selective Access to Electronic Medical Records
10. Lilly Diabetes Announces Once Upon A Time Contest Winner
11. Roche announces FDA approval of HIV viral load test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the German ... Germany , has purchased a MRIdian ... Clinic Heidelberg as part of its initiative for MRI-based ... be headed by Medical Director and Professor Jürgen Debus, ... German Cancer Research Center (DKFZ), the Heidelberg Heavy Ion ...
(Date:1/19/2017)... Jan. 19, 2017   Science Exchange , the ... announce that the first five replication studies from ... been published in eLife today. Despite intense scrutiny ... first practical evaluation of reproducibility rates that may ... Unlike other assessments of reproducibility, the results of ...
(Date:1/19/2017)... 19, 2017 New Review ... Address Motor Symptoms and Motor Complications in Mid- ... ... (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) C ... Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
Breaking Medicine Technology:
(Date:1/19/2017)... NJ (PRWEB) , ... January 19, 2017 , ... ... locally owned insurance agency which serves Lawrenceville, New Jersey and the surrounding area, ... , Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... 2017 Spring Create Real Impact contest from Impact Teen Drivers and California Casualty. ... http://www.createrealimpact.com . , Educational grants totaling $15,000 will be awarded for the ...
(Date:1/19/2017)... ... 2017 , ... Bill Howe Plumbing, Heating & Air in San Diego announces ... Healthy is Your Heart Drawing Contest The drawing contest asks children to draw ... Heating & Air receives over 600 entries. The culmination of the joint effort will ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sales Focus Inc. (SFI), a Maryland-based ... US market. , Over the past 20 years SFI has been recognized as the ... launched six new clients into the US market. The new clients include: Panacea ...
(Date:1/19/2017)... ... January 19, 2017 , ... Each year, the ... a conference where hundreds of surgeons from over fifteen different countries come together ... cosmetic breast augmentation to breast reconstruction for breast cancer patients, teaching ...
Breaking Medicine News(10 mins):